ArticleFunctional & integrative genomics2025
The role of chimeric FAM72B transcripts generated by intergenic mRNA trans-splicing in breast cancer.
Article in Functional & integrative genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Family with sequence similarity 72 (FAM72) is a protein-coding gene family located on chromosome 1 (chr1) in humans, and its functional roles, particularly in cancer, remain incompletely understood. Chimeric messenger RNA (mRNA) generated by intergenic mRNA trans-splicing (CRTS) is a novel phenomenon increasingly recognized for its involvement in cancer biology. It involves the fusion of two separate mRNA transcripts from different genomic loci, resulting in a chimeric mRNA molecule with altered functions. Since aging-related diseases, including various types of cancer, are major threats to our society, we investigated the functional significance of chimeric FAM72 fusion genes and their potential role in cancer cell proliferation with a focus on intergenic mRNA trans-splicing of FAM72 in cancer. We applied biocomputational analyses to identify chimeric FAM72 fusion genes across various cancer tissues. Whole-genome sequencing (WGS) and next-generation sequencing (NGS) of mRNA (RNA-seq) analysis were applied to identify novel chimeric FAM72 fusion genes at the genome (genomic structural variants or SVs) and/or mRNA level (trans-splicing). Our data supported the occurrence of novel chimeric adiponectin receptor-2 (ADIPOR2) :: FAM72B mRNA transcripts primarily produced through an intergenic mRNA trans-splicing event. Afterwards, we set up a breast cancer tissue-specific cell system to analyze the proliferative and migratory efficacy of cancer cells expressing these novel chimeric ADIPOR2::FAM72B mRNA fusion transcripts. Our findings suggest that the novel chimeric ADIPOR2::FAM72B mRNAs, generated by intergenic mRNA trans-splicing, can act as oncogenic drivers and represent promising diagnostic and therapeutic targets in breast cancer.
Indexed as
Identifiers
41329440What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.